Terlipressin in acute oesophageal variceal haemorrhage
- 19 December 2002
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (1) , 53-64
- https://doi.org/10.1046/j.1365-2036.2003.01356.x
Abstract
Summary: Background : Controversy exists surrounding pharmacological therapy in acute variceal bleeding.Aim : To determine the efficacy and safety of terlipressin.Methods : Randomized trials were identified and duplicate, independent, review identified 20 randomized trials involving 1609 patients that compared terlipressin with placebo, balloon tamponade, endoscopic treatment, octreotide, somatostatin or vasopressin for treatment of acute oesophageal variceal haemorrhage.Results : Meta‐analysis showed that compared to placebo, terlipressin reduced mortality (relative risk 0.66, 95% CI 0.49–0.88), failure of haemostasis (relative risk 0.63, 95% CI 0.45–0.89) and the number of emergency procedures per patient required for uncontrolled bleeding or rebleeding (relative risk 0.72, 95% CI 0.55–0.93). When used as an adjuvant to endoscopic sclerotherapy, terlipressin reduced failure of haemostasis (relative risk 0.75, 95% CI 0.58–0.96), and had an effect on reducing mortality that approached statistical significance (relative risk 0.74, 95% CI 0.53–1.04). No significant difference was demonstrated between terlipressin and endoscopic sclerotherapy, balloon tamponade, somatostatin or vasopressin. Haemostasis was achieved more frequently with octreotide compared to terlipressin (relative risk 1.62, 95% CI 1.05–2.50), but this result was based on unblinded studies. Adverse events were similar between terlipressin and the other comparison groups except for vasopressin, which caused more withdrawals due to adverse events.Conclusions : Terlipressin is a safe and effective treatment for acute oesophageal variceal bleeding, with or without adjuvant endoscopic sclerotherapy. Terlipressin appears to reduce mortality in acute oesophageal variceal bleeding compared to placebo, and is the only pharmacological agent shown to do so. Future studies will be required to detect potential mortality differences between terlipressin and other therapeutic approaches.Keywords
This publication has 29 references indexed in Scilit:
- Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST StudyHepatology, 2000
- Pharmacological Treatment of Portal Hypertension: An Evidence-Based ApproachSeminars in Liver Disease, 1999
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Published by Elsevier ,1998
- Time profile of the haemodynamic effects of terlipressin in portal hypertensionJournal of Hepatology, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis: A randomized clinical trialJournal of Hepatology, 1994
- Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double-blind studyHepatology, 1993
- A randomized controlled study of low‐dose and high‐dose terlipressin in the control of acute oesophageal variceal haemorrhageJournal of Gastroenterology and Hepatology, 1991
- A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varicesJournal of Gastroenterology and Hepatology, 1990
- Effects of lysine vasopressin and glypressin on the fibrinolytic system in cirrhosis.Gut, 1979